Therefore, the aim of this systematic review and meta-analysis is to evaluate the efficacy and safety of omalizumab as an adjunct to OIT in pediatric IgE-mediated food allergy, providing a comprehensive synthesis of available evidence to guide clinical decision-making and future research. This evidence concerns the gene IGHE and food allergy.